51 Institution Case Study Series With Tc-99m Tilmanocept for Efficiencies in Sentinel Lymph Node Biopsy

Publication
Article
Miami Breast Cancer Conference® Abstracts Supplement38th Annual Miami Breast Cancer Conference® - Abstracts
Volume 35
Issue suppl 1
Pages: 38

Vincent Reid, MD1; Sarah Pauley, MD, PhD2

1Hall-Perrine Cancer Center, Mercy Medical Center, Cedar Rapids, IA; vreid@mercycare.org

2Radiology Consultants of Iowa, Cedar Rapids, IA

Background

Our institution performed a series of case studies over 30 days of breast cancer (BC) patients undergoing preoperative lymphoscintigraphy and sentinel lymph node biopsy (SLNB) with receptor-targeted radiotracer, Tc-99m tilmanocept (Lymphoseek; Cardinal Health). Our protocol was a 2- to 2.5-hour window from injection to node detection for lumpectomy with SLNB, with 2 to 3 cases per surgical day. We wanted to evaluate if a change in radiotracer would change efficiency metrics.

Materials and Methods

Tc-99m tilmanocept injections were performed by one of several radiologists in nuclear medicine. The team tracked time on a card that traveled with the patient. A nuclear medicine technologist recorded the patient’s self-reported pain level immediately after injection on a scale of 1 (no pain) to 10 (maximum pain). In the first week, the trial duplicated existing time protocols (2 hours from injection to operating room [OR] node detection). The next phase determined how quickly the team could detect a signal. In week 2, the time between injection of the tracer and node detection was 1 hour. In week 3, that time was reduced to 30 minutes and results were evaluated.

Results

Across subjects with BC evaluated in the series (n = 8; Table), the mean time between injection and visualization of nodes was less than 20 minutes. The total time in the OR was reduced by 68.4 ± 8.6 minutes relative to previous experience with filtered Tc-99m sulfur colloid (FSC). The authors were able to detect the node(s) in each timeframe and with no change in signal intensity. In addition, patients consistently scored their pain levels between 1 and 2 out of 10.

TABLE. Tc-99m Tilmanocept Imaging and SLNB Summary Results

TABLE. Tc-99m Tilmanocept Imaging and SLNB Summary Results

Conclusions

These case studies with Tc-99m tilmanocept displayed short wait in nuclear medicine, short procedure times, and low patient-reported injection pain. We also noted specific signal intensity and high accuracy in detecting nodes with rapid injection site clearance and high patient satisfaction. As a result, Mercy Medical Center adopted Tc-99m tilmanocept using a 30-minute injection protocol for SLNB procedures. Morning surgeries start 2 hours earlier, allowing us to add 3 surgical cases per week.

Expert Commentary

Expert Commentary

Articles in this issue

1 The Tolerance of CREATE-X Capecitabine Dosing in a United States TNBC Patient Population
1 The Tolerance of CREATE-X Capecitabine Dosing in a United States TNBC Patient Population
6 Survival Benefit of Eribulin, But Not Capecitabine, for Metastatic Breast Cancer Is Associated With Baseline Absolute Lymphocyte Count in Peripheral Blood
6 Survival Benefit of Eribulin, But Not Capecitabine, for Metastatic Breast Cancer Is Associated With Baseline Absolute Lymphocyte Count in Peripheral Blood
7 Evaluation of the 21-Gene Recurrence Score (RS) Assay Results Following Successful Intraoperative Radiation Therapy (IORT) Treatment of Patients With Early-Stage Breast Cancer
7 Evaluation of the 21-Gene Recurrence Score (RS) Assay Results Following Successful Intraoperative Radiation Therapy (IORT) Treatment of Patients With Early-Stage Breast Cancer
8 Concordance of Tumor Response with Eribulin Use in Real-World Clinical Practice
8 Concordance of Tumor Response with Eribulin Use in Real-World Clinical Practice
13 Real-world Treatment Patterns and Tumor Response of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer: Flatiron Database Analysis
13 Real-world Treatment Patterns and Tumor Response of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer: Flatiron Database Analysis
14 Real-World (RW) Treatment Patterns and Clinical Effectiveness of Palbociclib (PAL) Plus an Aromatase Inhibitor (AI) as First-Line Therapy in Advanced/ Metastatic Breast Cancer (A/MBC): Analysis From Syapse Learning Health Network
14 Real-World (RW) Treatment Patterns and Clinical Effectiveness of Palbociclib (PAL) Plus an Aromatase Inhibitor (AI) as First-Line Therapy in Advanced/ Metastatic Breast Cancer (A/MBC): Analysis From Syapse Learning Health Network
25 A Retrospective Cohort Study of Demographic, Clinical, and Treatment Characteristics of Patients With Metastatic Breast Cancer Who Have Received PARP Inhibitors
25 A Retrospective Cohort Study of Demographic, Clinical, and Treatment Characteristics of Patients With Metastatic Breast Cancer Who Have Received PARP Inhibitors
28 Primary Outcome Analysis of Invasive Disease-Free Survival for monarchE: Abemaciclib Plus Adjuvant Endocrine Therapy for High-Risk Early Breast Cancer
28 Primary Outcome Analysis of Invasive Disease-Free Survival for monarchE: Abemaciclib Plus Adjuvant Endocrine Therapy for High-Risk Early Breast Cancer
30 Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Early- Stage Breast Cancer (ESBC) Receiving Docetaxel and Cyclophosphamide
30 Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Early- Stage Breast Cancer (ESBC) Receiving Docetaxel and Cyclophosphamide
35 Decreased Epithelial Mesenchymal Transition Process After AGTR-1 Gene Edition By Crispr/Cas9, Losartan, and PARP Inhibitor Treatment In Breast Cancer Cell Line
35 Decreased Epithelial Mesenchymal Transition Process After AGTR-1 Gene Edition By Crispr/Cas9, Losartan, and PARP Inhibitor Treatment In Breast Cancer Cell Line
37 Treatment Outcomes Using Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer in African American and Hispanic Women
37 Treatment Outcomes Using Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer in African American and Hispanic Women
42 The United States Retrospective Claims Database Analysis of Demographic, Clinical, and Treatment Characteristics of Metastatic Breast Cancer Patients receiving Olaparib
42 The United States Retrospective Claims Database Analysis of Demographic, Clinical, and Treatment Characteristics of Metastatic Breast Cancer Patients receiving Olaparib
43 Lobular Cancer Responsiveness to Chemotherapy Is Equivalent to That of Ductal Cancer With Similar Genomic Profiles: An NCDB Analysis
43 Lobular Cancer Responsiveness to Chemotherapy Is Equivalent to That of Ductal Cancer With Similar Genomic Profiles: An NCDB Analysis
44 Drivers of Oncologist Treatment Selection in HR+/HER2- Metastatic Breast Cancer
44 Drivers of Oncologist Treatment Selection in HR+/HER2- Metastatic Breast Cancer
45 Neoadjuvant Chemotherapy Use in Elderly Patients
45 Neoadjuvant Chemotherapy Use in Elderly Patients
Related Content